Table 1.
Study demographics, vascular parameters, CSF immunoassays, and imaging metrics at baseline
| Participants at baseline | 112 |
| 3 mo | 91% |
| 6 mo | 93% |
| 12 mo | 90% |
| 24 mo | 79% |
| Sex (male) | 59.1% |
| Age (y) | 73.2 (6.6) |
| Education (y) | 17 (2) |
| White—not Hispanic/Latino | 86.6% |
| APOE ε4 genotype | 27.9% |
| White matter hyperintensity volume at baseline | 6.30 (11.46) |
| 3 mo | 6.46 (10.94) |
| 6 mo | 6.21 (10.46) |
| 12 mo | 6.42 (12.02) |
| 24 mo | 6.78 (12.99) |
| Intracranial volume (ICV) (cm3) | 1504 (152) |
| CSF Aβ1–42 (pg/mL) at baseline | 202.6 (52.8) |
| 24 mo | 190.7 (51.3) |
| CSF t-tau (pg/mL) | 70.9 (38.8) |
| CSF p-tau181 (pg/mL) | 35.4 (20.8) |
| Current vascular status | |
| Body mass index | 28 (5) |
| Systolic blood pressure (mm Hg) | 136 (16) |
| Diastolic blood pressure (mm Hg) | 75 (10) |
| Fasting blood glucose (mg/dL) | 100 (18) |
| Total serum cholesterol (mg/dL) | 190 (35) |
| Vascular history | |
| Hypertension | 52.7% |
| Dyslipidemia | 40.2% |
| Diabetes mellitus | 8.0% |
| Smoking | 13.4% |
| MI/CVA/AF | 2.7% |
| Micro-hemorrhage | 14.3% |
All numerical entries are mean (standard deviation).
Key: AF, atrial fibrillation; CVA, stroke; MI, myocardial infarction.